CliffBio
small molecule

TRANEXAMIC ACID

TRANEXAMIC ACID

Loss of exclusivity—loss of exclusivity
CompanyNexus Labs →See this company's full patent-cliff portfolio

Drug detail

Brand nameTRANEXAMIC ACID
Active ingredientTRANEXAMIC ACID
Strength1GM/100ML (10MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalApril 2024
Marketing statusRX

More from Nexus Labs

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TRANEXAMIC ACID patent cliff — loss of exclusivity — | CliffBio